# Severe Manifestation of Hyperparathyroidism With Sagliker Syndrome: A Case Report

**Authors:** Mario Manuel Morantes Salazar, Jenny Carolina Salazar Florez, Nathalia Jacome-Pérez, William Darío Arenas Borda, Camilo Andrés Lara Rodríguez

PMC · DOI: 10.7759/cureus.101753 · 2026-01-17

## TL;DR

A 26-year-old woman with kidney disease developed severe facial deformities due to Sagliker syndrome, a rare condition linked to high parathyroid hormone levels.

## Contribution

This case highlights the importance of early recognition and multidisciplinary management of Sagliker syndrome.

## Key findings

- The patient had markedly elevated parathyroid hormone levels (1,936 pg/mL) and characteristic cranial imaging features.
- A multidisciplinary approach including parathyroidectomy was necessary to manage persistent biochemical abnormalities.
- Early diagnosis is critical to prevent irreversible craniofacial deformities and long-term complications.

## Abstract

Sagliker syndrome represents a rare and severe manifestation of secondary renal osteodystrophy in patients with end-stage chronic kidney disease. We present the case of a 26-year-old woman on peritoneal dialysis with a one-year history of progressive craniofacial deformity involving both the maxilla and mandible. Laboratory tests demonstrated markedly elevated parathyroid hormone levels (1,936 pg/mL). Cranial CT revealed a diffuse “salt and pepper” pattern, serpiginous lytic trabecular changes, and focal ground-glass areas in the calvarium. Correlation of severe hyperparathyroidism with these characteristic imaging features confirmed Sagliker syndrome. Early recognition is essential to prevent irreversible deformities and long-term morbidity. The patient was managed through a multidisciplinary approach, including medical optimization of secondary hyperparathyroidism, followed by total parathyroidectomy due to persistent biochemical abnormalities and progressive craniofacial deformity.

## Linked entities

- **Diseases:** Sagliker syndrome (MONDO:0017584), hyperparathyroidism (MONDO:0001741)

## Full-text entities

- **Genes:** GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, FGFR3 (fibroblast growth factor receptor 3) [NCBI Gene 2261] {aka ACH, CD333, CEK2, HSFGFR3EX, JTK4}
- **Diseases:** inflammatory (MESH:D007249), SS (MESH:D013577), Fibrous dysplasia (MESH:D005357), vertebral compression (MESH:D009408), Hyperparathyroidism (MESH:D006961), pain (MESH:D010146), Brown tumors (MESH:D009369), Cytogenetic abnormalities (MESH:D002869), dyspnea (MESH:D004417), inflammatory, or systemic disease (MESH:D018746), psychiatric (MESH:D001523), advanced renal failure (MESH:D051437), anxiety (MESH:D001007), Secondary hyperparathyroidism (MESH:D006962), CKD (MESH:D051436), lytic lesions (MESH:D009059), skeletal abnormalities (MESH:D009139), metabolic bone disease (MESH:D001851), vitamin D deficiency (MESH:D014808), dental abnormalities (MESH:D014071), loss of renal function (MESH:D058186), Paget's disease (MESH:C537701), fever (MESH:D005334), craniofacial deformities (MESH:D005157), neurosensory deficits (MESH:D006319), hearing impairment (MESH:D034381), Class II malocclusion (MESH:D008312), hypocalcemia (MESH:D006996), dysphagia (MESH:D003680), malnutrition (MESH:D044342), nasal bone destruction (MESH:C562753), hypertension (MESH:D006973), end stage renal disease"[All (MESH:D007676), maxillofacial deformities (MESH:D008446), mineral and bone disorder (MESH:D012080), craniofacial bone abnormalities (MESH:D019465), weight loss (MESH:D015431), bone disease (MESH:D001847), leontiasis ossea"[All (MESH:D006957), impaired calcium-phosphate homeostasis (MESH:D002128), depression (MESH:D003866), deformity (MESH:D009140), hyperphosphatemia (MESH:D054559), hyperplasia (MESH:D006965), insufficiency fractures (MESH:D015775), infectious (MESH:D003141), Sagliker syndrome"[All (MESH:C536496), -tissue (MESH:D017695), neurological deterioration (MESH:D009422), cognitive deterioration (MESH:D003072)
- **Chemicals:** Vitamin D (MESH:D014807), phosphate (MESH:D010710), calcitriol (MESH:D002117)
- **Species:** Meleagris gallopavo (common turkey, species) [taxon 9103], Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12909286/full.md

---
Source: https://tomesphere.com/paper/PMC12909286